Lilly and BioArctic sign deal to develop neurodegenerative therapy

Eli Lilly and Company has signed a research agreement with BioArctic to develop a potential treatment for neurodegenerative diseases. BioArctic will create a new drug candidate using its BrainTransporter platform and Lilly’s molecule. The BrainTransporter technology is built to help drugs cross the blood-brain barrier by targeting the transferrin receptor. Credit: Komsan Loonprom / Shutterstock.com. Eli Lilly and Company has signed a research and collaboration agreement with Swedish biopharmaceutical company BioArctic to develop a potential treatment for neurodegenerative diseases. The partnership will combine BioArctic’s BrainTransporter technology with an unidentified Lilly drug candidate. NPVM: Denali Therapeutics Inc's DNL-343 Reports NPVM: SanBio…

Salong Debbarma · 2026-06-23

Eli Lilly and Company has signed a research agreement with BioArctic to develop a potential treatment for neurodegenerative diseases.

Source: Pharmaceutical Technology